Oncology Institute Management
Management criteria checks 3/4
Oncology Institute's CEO is Dan Virnich, appointed in Jun 2023, has a tenure of 1.67 years. total yearly compensation is $808.13K, comprised of 56.3% salary and 43.7% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $396.71K. The average tenure of the management team and the board of directors is 1.5 years and 3.3 years respectively.
Key information
Dan Virnich
Chief executive officer
US$808.1k
Total compensation
| CEO salary percentage | 56.3% |
| CEO tenure | 1.7yrs |
| CEO ownership | 0.5% |
| Management average tenure | 1.5yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 195% But Many Are Still Ignoring The Company
Jan 18
A Piece Of The Puzzle Missing From The Oncology Institute, Inc.'s (NASDAQ:TOI) 28% Share Price Climb
Jul 19The Oncology Institute, Inc. (NASDAQ:TOI) Stock's 29% Dive Might Signal An Opportunity But It Requires Some Scrutiny
May 05Not Many Are Piling Into The Oncology Institute, Inc. (NASDAQ:TOI) Stock Yet As It Plummets 28%
Mar 21Is Oncology Institute (NASDAQ:TOI) A Risky Investment?
Mar 05The Oncology Institute, Inc. (NASDAQ:TOI) Stock Rockets 49% But Many Are Still Ignoring The Company
Nov 10The Oncology Institute swings to Q2 GAAP loss per share from year-ago profit
Aug 09Shareholders Shouldn’t Be Too Comfortable With Oncology Institute's (NASDAQ:TOI) Strong Earnings
May 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$57m |
| Jun 30 2024 | n/a | n/a | -US$59m |
| Mar 31 2024 | n/a | n/a | -US$60m |
| Dec 31 2023 | US$808k | US$455k | -US$68m |
| Sep 30 2023 | n/a | n/a | -US$61m |
| Jun 30 2023 | n/a | n/a | -US$50m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$3m | US$446k | US$68k |
| Sep 30 2022 | n/a | n/a | -US$1m |
| Jun 30 2022 | n/a | n/a | -US$2m |
| Mar 31 2022 | n/a | n/a | US$6m |
| Dec 31 2021 | US$8m | US$263k | -US$11m |
| Sep 30 2021 | n/a | n/a | -US$6m |
| Jun 30 2021 | n/a | n/a | -US$3m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$419k | US$214k | -US$14m |
Compensation vs Market: Dan's total compensation ($USD808.13K) is about average for companies of similar size in the US market ($USD640.92K).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Virnich (45 yo)
1.7yrs
Tenure
US$808,129
Compensation
Dr. Daniel Virnich, also known as Dan, M.D., M.B.A., FACHE, is Chief Executive Officer of The Oncology Institute Inc. since June 2023 and serves as its Executive Director since June 13, 2024. He served as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 5.3yrs | US$162.40k | 0.45% $ 337.2k | |
| CEO & Executive Director | 1.7yrs | US$808.13k | 0.53% $ 396.7k | |
| Chief Medical Officer | 3.3yrs | US$591.28k | 0.031% $ 23.8k | |
| Chief Financial Officer | less than a year | no data | 0.010% $ 7.7k | |
| Chief Operations Officer | 1.4yrs | no data | 0.0026% $ 2.0k | |
| General Counsel | 10.1yrs | no data | no data | |
| Chief Development Officer | less than a year | no data | no data |
1.5yrs
Average Tenure
48.5yo
Average Age
Experienced Management: TOI's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 5.3yrs | US$162.40k | 0.45% $ 337.2k | |
| CEO & Executive Director | less than a year | US$808.13k | 0.53% $ 396.7k | |
| Independent Director | 2.4yrs | US$160.32k | 0.11% $ 84.4k | |
| Vice Chairman | 3.3yrs | US$1.34m | 0.55% $ 417.5k | |
| Independent Director | 3.3yrs | US$188.81k | 0.17% $ 127.3k | |
| Director | 2.4yrs | US$143.70k | 0.091% $ 69.1k | |
| Independent Director | 4.9yrs | US$180.22k | 0.16% $ 121.2k | |
| Independent Director | 3.3yrs | US$177.53k | 0.15% $ 115.2k |
3.3yrs
Average Tenure
62.5yo
Average Age
Experienced Board: TOI's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 01:52 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
The Oncology Institute, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Draper | Guggenheim Securities, LLC |
| Brian Tanquilut | Jefferies LLC |